読み込み中
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
前日終値
$1.41
$0.00 · 0.00%
時間外
$1.40
−$0.01 · -0.71%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
日中レンジ
現在 $1.41
52週レンジ
現在 $1.41
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
77
割安
センチメント
28
弱気
リスク
76
高リスク
モメンタム
56
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
日中レンジ
現在 $1.41
52週レンジ
現在 $1.41
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7038.7万 USD | 5934.5万 USD | 7014.3万 USD | 1.39億 USD | 1.05億 USD |
| 売上原価 | 933.8万 USD | 1628.8万 USD | 1280.9万 USD | 3803.3万 USD | 2220.9万 USD |
| 粗利益 | 6104.9万 USD | 4305.7万 USD | 5733.4万 USD | 1.01億 USD | 8254.5万 USD |
| 研究開発 | 5230.7万 USD | 4626.3万 USD | 5888.5万 USD | 8009.9万 USD | 5591.9万 USD |
| 販売・一般管理 | 4707.4万 USD | 5514.8万 USD | 5325万 USD | 5217.2万 USD | 4932.3万 USD |
| 営業費用 | 9938.1万 USD | 1.02億 USD | 1.25億 USD | 1.35億 USD | 1.05億 USD |
| 受取利息 | 262.5万 USD | 367万 USD | 417.2万 USD | 144.1万 USD | 45.9万 USD |
| 支払利息 | 481.3万 USD | — | — | — | — |
| 減価償却費と償却費 | 524.8万 USD | 494.6万 USD | 992.3万 USD | 1025.1万 USD | 594.7万 USD |
| 営業利益 | −3833.2万 USD | −5851.9万 USD | −6806.9万 USD | −3488.1万 USD | −2269.7万 USD |
| 純利益 | −4397.4万 USD | −6527.6万 USD | −7624万 USD | −3359.2万 USD | −2127.9万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.00
上昇余地（467.38%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI523.44万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM360.36万0.00%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF154.26万0.00%954億 USD0.05%$233.52-0.63%
iShares Russell 2000 Growth ETFIWO112.54万0.01%139.17億 USD0.24%$353.71-0.86%
iShares Biotechnology ETFIBB111.44万0.01%108.2億 USD0.44%$204.26-1.08%
Vanguard Russell 2000 ETFVTWO84.66万0.00%180億 USD0.06%$112.27-0.35%
iShares Micro-Cap ETFIWC44.99万0.03%13.17億 USD0.60%$181.66-0.73%
Fidelity Enhanced Small Cap ETFFESM25.34万—64.1億 USD0.28%$45.24-0.48%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
